DOCSLIB.ORG

Therapeutic Fibrinolysis How Efficacy and Safety Can Be Improved

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Fibrinolysis How Efficacy and Safety Can Be Improved JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL.68,NO.19,2016 ª 2016 PUBLISHED BY ELSEVIER ON BEHALF OF THE ISSN 0735-1097/$36.00 AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION http://dx.doi.org/10.1016/j.jacc.2016.07.780 THE PRESENT AND FUTURE REVIEW TOPIC OF THE WEEK Therapeutic Fibrinolysis How Efficacy and Safety Can Be Improved Victor Gurewich, MD ABSTRACT Therapeutic fibrinolysis has been dominated by the experience with tissue-type plasminogen activator (t-PA), which proved little better than streptokinase in acute myocardial infarction. In contrast, endogenous fibrinolysis, using one-thousandth of the t-PA concentration, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 patency in 15% of patients with acute myocardial infarction. This efficacy is due to the effects of t-PA and urokinase plasminogen activator (uPA). They are complementary in fibrinolysis so that in combination, their effect is synergistic. Lysis of intact fibrin is initiated by t-PA, and uPA activates the remaining plasminogens. Knockout of the uPA gene, but not the t-PA gene, inhibited fibrinolysis. In the clinic, a minibolus of t-PA followed by an infusion of uPA was administered to 101 patients with acute myocardial infarction; superior infarct artery patency, no reocclusions, and 1% mortality resulted. Endogenous fibrinolysis may provide a paradigm that is relevant for therapeutic fibrinolysis. (J Am Coll Cardiol 2016;68:2099–106) © 2016 Published by Elsevier on behalf of the American College of Cardiology Foundation. n occlusive intravascular thrombus triggers fibrinolysis, as shown by it frequently not being A the cardiovascular diseases that are the lead- identified specifically in publications on clinical ing causes of death and disability worldwide. fibrinolysis. The only pharmacological means to remove the The anticipated benefits of t-PA were never ful- thrombus is fibrinolysis. There are 2 plasminogen filled, and it has been largely replaced by percuta- activators in the blood responsible for fibrinolysis: neous coronary intervention (PCI) as the treatment of tissue-type plasminogen activator (t-PA) and uroki- choice for AMI in urban centers in the United States, nase plasminogen activator (uPA). They exist in although it is still used in rural areas too far from a both single-chain and plasmin-cleaved 2-chain forms. catheterization facility. As pre-treatment, or facili- With t-PA, both forms have the same activity (1), tated PCI, t-PA significantly increased both throm- whereas the single-chain form of uPA is a proenzyme botic and hemorrhagic complications of PCI (7),and (pro-uPA) and the 2-chain form is an active enzyme itsusehasbeendiscouraged.Inischemicstroke,t-PA (2-chain uPA, the enzymatic form of uPA [tc-uPA]) (2). is used in only about 5% of patients (8), and in venous The fibrin specificity of t-PA is mediated by high thromboembolism, a hemorrhagic risk has limited its fibrin affinity (3,4), which promotes plasminogen use to patients with hemodynamic instability due to activating activity about a thousand-fold (5).Itwas the emboli (9). the first fibrin-specific plasminogen activator, and The enzymatic form of uPA, tc-uPA, has been became the first recombinant protein on the market known since the 1940s as a nonspecific activator, like (6). The clinical experience with t-PA in acute streptokinase (SK), which caused bleeding complica- Listen to this manuscript’s myocardial infarction (AMI), ischemic stroke, and tions. The single-chain uPA proenzyme, pro-uPA, was audio summary by venous thromboembolism has been extensive. As a not identifiedandisolateduntil1980(10).Ithasno JACC Editor-in-Chief result, t-PA became essentially equated with fibrin affinity, but is nevertheless fibrin specific (11). Dr. Valentin Fuster. From the Vascular Research Laboratory, Mount Auburn Hospital, Cambridge, Massachusetts, and Harvard Medical School, Cam- bridge, Massachusetts. Dr. Gurewich has reported that he has no relationships relevant to the contents of this paper to disclose. Manuscript received July 14, 2016; accepted July 20, 2016. 2100 Gurewich JACC VOL. 68, NO. 19, 2016 Improving Fibrinolysis NOVEMBER 8, 2016:2099– 106 ABBREVIATIONS Being a proenzyme, it remains inert in blood A special challenge for primary PCI treatment is AND ACRONYMS until it reaches a clot, a pharmacologically reducing the time to reperfusion. Reduction in AMI advantageous property. Unfortunately, this mortality is greatest if reperfusion is accomplished AMI = acute myocardial infarction property is undermined by dose-dependent within 1 to 2 h of symptom onset (27),andin plasma instability, because it activates patients who received reperfusion treatment within ICH = intracranial hemorrhage plasma plasminogen at certain therapeutic 70 min of symptom onset, the mortality was 1.2% PCI = percutaneous coronary intervention concentrations, and plasmin converts pro- (28). In animal models, the longer the coronary uPA to tc-uPA. For example, in a study occlusion, the less salvageable myocardium remains pro-uPA = proenzyme urokinase plasminogen where pro-uPA and SK were compared in (29). Therefore, pre-treatment was tested. activator AMI, bleeding complications occurred in 14% FACILITATED PCI WITH t-PA SK = streptokinase of the pro-uPA patients, of whom 4% tc-uPA = 2-chain urokinase required transfusions and 2 patients had an Although t-PA pre-treatment doubled the number of plasminogen activator, the intracranial hemorrhage (ICH) (12).Atphysi- enzymatic form of uPA patients with initial TIMI flow grade 3 patency, the ological and lower therapeutic concentra- TIMI = Thrombolysis In final TIMI flow grade 3 patency rates did not differ in tions, pro-uPA is stable in plasma and is an Myocardial Infarction the 2 groups (89% vs. 88%), consistent with t-PA’s essential component of the endogenous t-PA = tissue-type significant rethrombosis rate (17). In addition, more plasminogen activator fibrinolytic system. bleeding, reinfarctions, and strokes occurred with uPA = urokinase plasminogen FIBRINOLYSIS WITH t-PA facilitated PCI (30). By contrast, with pro-uPA, neither activator a prothrombotic effect nor reocclusions were found in The U.S. Food and Drug Administration approved AMI (31), suggesting that the complications were t-PA for AMI treatment in 1987 but, to show that it related to t-PA rather than to fibrinolysis. reduced mortality compared with SK, additional It was concluded that t-PA facilitated PCI offered clinical trials were performed starting in 1990. Three no benefit, an outcome lamented in a commentary in megatrials with an unprecedented total of 95,740 a prominent journal as “Facilitated angioplasty: patients were required before a significant p value paradise lost” (32), because there is no alternative to was reached for a mortality difference (13–15).This shorten the time to reperfusion. was in only 1 of 4 groups in the last trial, in which an Interestingly, these studies found that in 15% of accelerated rate of t-PA infusion induced a significant patients with ST-segment elevation myocardial 30-day mortality difference (6.3% vs. 7.0%) (15).Also infarction, TIMI flow grade 3 was already found at the unexpected was the finding that the ICH rate was time of the primary PCI (33), and these patients fared significantly higher with t-PA than SK, despite the significantly better (24,25). This illustrates the effi- nonspecific and indirect mode of action of SK. These cacy of endogenous fibrinolysis in which the t-PA results did not stand up to a Bayesian analysis, which concentration is $1,000-fold lower than the thera- concluded, “the clinical superiority of t-PA over SK peutic one. remains uncertain” (16). t-PA FIBRINOLYSIS INISCHEMICSTROKE As heralded by these trials, t-PA’s limited efficacy— a16Æ 10% reocclusion rate (17)—prothrombotic he- In ischemic stroke, a t-PA dose reduction was matologic effects, such as thrombin generation and required due to a 20% symptomatic ICH incidence platelet activation (18–22), and bleeding side effects, whentheusualAMIdosewasused(34).Asaresult, such as ICH, led to alternative therapies. the t-PA recanalization decreased 30% to 40%, PCI VERSUS t-PA making it ineffective for larger thrombi in proximal occlusions (35,36).Evenatthereduceddose,the In a review of 23 PCI trials involving 7,739 patients, symptomatic ICH rate was 6% to 7% (37). 3,867 were randomized to treatment with fibrinolysis In the largest trial, 1,500 patients per group were (2,939 with t-PA, 928 with SK) and 3,872 patients to randomized to t-PA or standard care and treated within primary PCI (23).Asignificantly better outcome was 6 h. The proportion of patients alive and living inde- obtained with PCI for both the short-term and long- pendently at 6 months was 37% with t-PA and 35% term outcomes. The post-treatment Thrombolysis In for the controls. Although insignificant, a secondary Myocardial Infarction (TIMI) flow grade 3, an impor- ordinal analysis found a significant (p < 0.001) favor- tant predictor of good outcome (24,25),wasalso able shift in the functional score in the t-PA–treated significantly better with PCI than in the GUSTO (Global patients, but more patients died with t-PA in the first Utilization of Streptokinase and Tissue Plasminogen 7days(11%vs.7%;p¼ 0.001) (38).Theauthors Activator for Occluded Coronary Arteries) trial (26). concluded that early treatment with t-PA should be JACC VOL. 68, NO. 19, 2016 Gurewich 2101 NOVEMBER 8, 2016:2099– 106 Improving Fibrinolysis encouraged, but others were more skeptical, including Catheter placement within the thrombus is a prereq-
Load more

Recommended publications
  • Role of the Renin–Angiotensin–Aldosterone and Kinin–Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID
    International Journal of Molecular Sciences Review Role of the Renin–Angiotensin–Aldosterone and Kinin–Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID Samantha L. Cooper 1,2,*, Eleanor Boyle 3, Sophie R. Jefferson 3, Calum R. A. Heslop 3 , Pirathini Mohan 3, Gearry G. J. Mohanraj 3, Hamza A. Sidow 3, Rory C. P. Tan 3, Stephen J. Hill 1,2 and Jeanette Woolard 1,2,* 1 Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK; [email protected] 2 Centre of Membrane Proteins and Receptors (COMPARE), School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK 3 School of Medicine, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK; [email protected] (E.B.); [email protected] (S.R.J.); [email protected] (C.R.A.H.); [email protected] (P.M.); [email protected] (G.G.J.M.); [email protected] (H.A.S.); [email protected] (R.C.P.T.) * Correspondence: [email protected] (S.L.C.); [email protected] (J.W.); Tel.: +44-115-82-30080 (S.L.C.); +44-115-82-31481 (J.W.) Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible Citation: Cooper, S.L.; Boyle, E.; for the COVID-19 pandemic. Patients may present as asymptomatic or demonstrate mild to severe Jefferson, S.R.; Heslop, C.R.A.; and life-threatening symptoms. Although COVID-19 has a respiratory focus, there are major cardio- Mohan, P.; Mohanraj, G.G.J.; Sidow, vascular complications (CVCs) associated with infection.
    [Show full text]
  • Urokinase, a Promising Candidate for Fibrinolytic Therapy for Intracerebral Hemorrhage
    LABORATORY INVESTIGATION J Neurosurg 126:548–557, 2017 Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage *Qiang Tan, MD,1 Qianwei Chen, MD1 Yin Niu, MD,1 Zhou Feng, MD,1 Lin Li, MD,1 Yihao Tao, MD,1 Jun Tang, MD,1 Liming Yang, MD,1 Jing Guo, MD,2 Hua Feng, MD, PhD,1 Gang Zhu, MD, PhD,1 and Zhi Chen, MD, PhD1 1Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing; and 2Department of Neurosurgery, 211st Hospital of PLA, Harbin, People’s Republic of China OBJECTIVE Intracerebral hemorrhage (ICH) is associated with a high rate of mortality and severe disability, while fi- brinolysis for ICH evacuation is a possible treatment. However, reported adverse effects can counteract the benefits of fibrinolysis and limit the use of tissue-type plasminogen activator (tPA). Identifying appropriate fibrinolytics is still needed. Therefore, the authors here compared the use of urokinase-type plasminogen activator (uPA), an alternate thrombolytic, with that of tPA in a preclinical study. METHODS Intracerebral hemorrhage was induced in adult male Sprague-Dawley rats by injecting autologous blood into the caudate, followed by intraclot fibrinolysis without drainage. Rats were randomized to receive uPA, tPA, or saline within the clot. Hematoma and perihematomal edema, brain water content, Evans blue fluorescence and neurological scores, matrix metalloproteinases (MMPs), MMP mRNA, blood-brain barrier (BBB) tight junction proteins, and nuclear factor–κB (NF-κB) activation were measured to evaluate the effects of these 2 drugs in ICH. RESULTS In comparison with tPA, uPA better ameliorated brain edema and promoted an improved outcome after ICH.
    [Show full text]
  • Fibrinolysis and Anticoagulant Potential of a Metallo Protease Produced by Bacillus Subtilis K42
    Fibrinolysis and anticoagulant potential of a metallo protease produced by Bacillus subtilis K42 WESAM AHASSANEIN, ESSAM KOTB*, NADIA MAWNY and YEHIA AEL-ZAWAHRY Department of Microbiology, Faculty of Science, Zagazig University, Zagazig, Egypt 44519 *Corresponding author (Email, [email protected]) In this study, a potent fibrinolytic enzyme-producing bacterium was isolated from soybean flour and identified as Bacillus subtilis K42 and assayed in vitro for its thrombolytic potential. The molecular weight of the purified enzyme was 20.5 kDa and purification increased its specific activity 390-fold with a recovery of 14%. Maximal activity was attained at a temperature of 40°C (stable up to 65°C) and pH of 9.4 (range: 6.5–10.5). The enzyme retained up to 80% of its original activity after pre-incubation for a month at 4°C with organic solvents such as diethyl ether (DE), toluene (TO), acetonitrile (AN), butanol (BU), ethyl acetate (EA), ethanol (ET), acetone (AC), methanol (ME), isopropanol (IP), diisopropyl fluorophosphate (DFP), tosyl-lysyl-chloromethylketose (TLCK), tosyl-phenylalanyl chloromethylketose (TPCK), phenylmethylsulfonylfluoride (PMSF) and soybean trypsin inhibitor (SBTI). Aprotinin had little effect on this activity. The presence of ethylene diaminetetraacetic acid (EDTA), a metal-chelating agent and two metallo protease inhibitors, 2,2′-bipyridine and o-phenanthroline, repressed the enzymatic activity significantly. This, however, could be restored by adding Co2+ to the medium. The clotting time of human blood serum in the presence of this enzyme reached a relative PTT of 241.7% with a 3.4-fold increase, suggesting that this enzyme could be an effective antithrombotic agent.
    [Show full text]
  • Clinical Protocol
    CLINICAL PROTOCOL Subject: Page Protocol # EMERGENT TREATMENT OF PATIENTS WITH BLEEDING AND 1 of 4 NMH CCP 07.0024 CLOTTING EMERGENCIES WHO ARE TAKING NOVEL ORAL ANTICOAGULANTS Version: 1.0 Title: Revision of: Effective Date: EMERGENT TREATMENT OF PATIENTS WITH BLEEDING AND NEW 04/29/2013 CLOTTING EMERGENCIES WHO ARE TAKING NOVEL ORAL Removal Date: ANTICOAGULANT APIXABAN (ELIQUIS) I. PURPOSE: To standardize management of patients with bleeding and clotting emergencies who are taking novel oral anticoagulants (NOACs). This protocol covers emergent reversal and ischemic stroke in patients on apixaban (Eliquis) therapy. II. CLINICAL PROTOCOL: A. The NOAC apixaban (Eliquis) is FDA approved for stroke prevention in patients with atrial fibrillation. This agent presents clinicians with several challenges because there are no specific antidotes, and no readily available quantitative assay to determine the degree of anticoagulation in a patient on this therapy. B. Patients taking this agent are likely to present to the hospital with; 1. life-threatening bleeding (e.g., intracerebral hemorrhage or GI bleeding), or a need for an emergent invasive procedure (surgery, cardiac Catherization) 2. acute ischemic stroke. The administration of tissue plasminogen activator (IV tPA) in the setting of NOAC use is potentially dangerous. C. There are no accepted evidence-based guidelines for managing these situations. This protocol is a consensus of clinicians from stroke, neurology, neurosurgery, hematology, neurocritical care, laboratory medicine, cardiology, and pharmacy. III. REVERSAL PROTOCOL FOR PATIENTS WITH SEVERE/LIFE-THREATENING BLEEDING TAKING APIXABAN (ELIQUIS) A. Inclusion criteria: 1. Patient has taken any dose of apixaban within last 48 hours. a. If time of last dose is unknown, but patient is suspected of having taken apixaban in last 48 hours, and PT is abnormal and 2.
    [Show full text]
  • Role of Thrombin and Thromboxane A2 in Reocclusion Following Coronary
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 7585-7589, October 1989 Medical Sciences Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator (thrombolytic therapy/coronary thrombosis/platelet activation/reperfusion) DESMOND J. FITZGERALD*I* AND GARRET A. FITZGERALD* Divisions of *Clinical Pharmacology and tCardiology, Vanderbilt University, Nashville, TN 37232 Communicated by Philip Needleman, June 28, 1989 (receivedfor review April 12, 1989) ABSTRACT Reocclusion of the coronary artery occurs against the prothrombinase formed on the platelet surface after thrombolytic therapy of acute myocardlal infarction (13) and the neutralization ofheparin by platelet factor 4 (14) despite routine use of the anticoagulant heparin. However, and thrombospondin (15), proteins released by activated heparin is inhibited by platelet activation, which is greatly platelets. enhanced in this setting. Consequently, it is unclear whether To address the role of thrombin during coronary throm- thrombin induces acute reocclusion. To address this possibility, bolysis, we have examined the effect of a specific thrombin we examined the effect of argatroban {MCI9038, (2R,4R)- inhibitor, argatroban {MCI9038, (2R,4R)-4-methyl-1-[N-(3- 4-methyl-l-[Na-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfo- methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2- nyl)-L-arginyl]-2-piperidinecarboxylic acid}, a specific throm- piperidinecarboxylic acid} on the response to tissue plasmin- bin inhibitor, on the response to tissue-type plasminogen ogen activator (t-PA) in a closed-chest canine model of activator in a dosed-chest canine model of coronary thrombo- coronary thrombosis. MCI9038, an argimine derivative which sis. MCI9038 prolonged the thrombin time and shortened the binds to a hydrophobic pocket close to the active site of time to reperfusion (28 + 2 min vs.
    [Show full text]
  • 2-Diss Preface1
    Purification and preliminary characterization of Bothrops moojeni venom components active on haemostasis (Botmo Thesis) Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Anna Maria Perchu ć aus Warschau, Polen Referent: Prof. Dr. Beat Ernst Korreferent: Prof. Dr. phil. Jürg Meier Basel, 2010 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Herrn Prof. Dr. Beat Ernst und Herrn Prof. Dr. phil. Jürg Meier Basel, den 16. September 2008 Prof. Dr. Eberhard Parlow Dekan Wissenschaft ist der gegenwärtige Stand unseres Irrtums Jakob Franz Kern (1897-1924) Anna Maria Perchuć – Botmo Thesis I Acknowledgements To my Doktorvater Prof. Dr. Beat Ernst for his patience, support and scientific advice. To Prof. Dr. phil. Jürg Meier (my Korreferent) and to Prof. Dr. Reto Brun for their input to my PhD exam. To Pentaphatm Ltd. for giving me the opportunity to work on the “Bothrops moojeni Venom Proteomics Project”. To Marianne and Bea for helpful discussions, scientific, practical and personal support, their enthusiasm and friendship. To Reto for giving me the encouragement and guidance and for coordinating the Botmo Project. To the whole Hämostase und Test-Kit-Entwicklung Team for their friendly and helpful cooperation. To Laure, Reto, Philou and the whole Atheris Team for their scientific assistance. To Marc and his Synthesis Team for their involvement in the Botmo Project, their help, support and sense of humour. To Uwe and Andre for the fruitful cooperation. To Andreas for his great assistance and many valuable suggestions. To Remo and Martin for their support in the cell culture lab.
    [Show full text]
  • Systemic Thrombolysis in a Patient with Massive Pulmonary Embolism and Recent Glioblastoma Multiforme Resection
    Unusual presentation of more common disease/injury BMJ Case Reports: first published as 10.1136/bcr-2017-221578 on 29 November 2017. Downloaded from CASE REPORT Systemic thrombolysis in a patient with massive pulmonary embolism and recent glioblastoma multiforme resection Joshua Lampert,1 Behnood Bikdeli,2 Philip Green,3 Matthew R Baldwin4 1Department of Internal SUMMARY and 2013 American College of Cardiology Foun- Medicine, Columbia University While trials of systemic thrombolysis for submassive and dation/AHA Task Force on Practice Guidelines list Medical Center, New York City, massive pulmonary embolism (PE) report intracranial known malignant intracranial neoplasm and brain New York, USA haemorrhage (ICH) rates of 2%–3%, the risk of ICH or spinal canal surgery within 2 months as absolute 2Division of Cardiology, in patients with recent brain surgery or intracranial contraindications to thrombolysis for treatment Columbia University Medical 8 9 Center, New York, NY neoplasm is unknown since these patients were of PE and ST-elevation myocardial infarction. 3Division of Cardiology, excluded from these trials. We report a case of massive The Neurocritical Care Society does not provide Columbia University Medical PE treated with systemic thrombolysis in a patient with guidelines for treatment of venous thromboembo- Center, New York, NY recent neurosurgery for an intracranial neoplasm. We lism (VTE). While the ACCP guidelines note that 4Division of Pulmonary discuss the risks and benefits of systemic thrombolysis the more severe the hypotension, the more compel- and Critical Care Medicine, for massive PE in the context of previous case reports, ling the indication for systemic thrombolysis, there Columbia University College of prior cohort studies and trials, and current guidelines.
    [Show full text]
  • The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’S Perspective
    International Journal of Molecular Sciences Review The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective Hau C. Kwaan 1,* and Paul F. Lindholm 2 1 Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA 2 Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] * Correspondence: [email protected] Abstract: The novel coronavirus disease (COVID-19) has many characteristics common to those in two other coronavirus acute respiratory diseases, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). They are all highly contagious and have severe pulmonary complications. Clinically, patients with COVID-19 run a rapidly progressive course of an acute respiratory tract infection with fever, sore throat, cough, headache and fatigue, complicated by severe pneumonia often leading to acute respiratory distress syndrome (ARDS). The infection also involves other organs throughout the body. In all three viral illnesses, the fibrinolytic system plays an active role in each phase of the pathogenesis. During transmission, the renin-aldosterone- angiotensin-system (RAAS) is involved with the spike protein of SARS-CoV-2, attaching to its natural receptor angiotensin-converting enzyme 2 (ACE 2) in host cells. Both tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 (PAI-1) are closely linked to the RAAS. In lesions in the lung, kidney and other organs, the two plasminogen activators urokinase-type plasminogen activator (uPA) and tissue plasminogen activator (tPA), along with their inhibitor, plasminogen activator 1 (PAI-1), are involved. The altered fibrinolytic balance enables the development of a hypercoagulable Citation: Kwaan, H.C.; Lindholm, state.
    [Show full text]
  • Biomechanical Thrombosis: the Dark Side of Force and Dawn of Mechano-­ Medicine
    Open access Review Stroke Vasc Neurol: first published as 10.1136/svn-2019-000302 on 15 December 2019. Downloaded from Biomechanical thrombosis: the dark side of force and dawn of mechano- medicine Yunfeng Chen ,1 Lining Arnold Ju 2 To cite: Chen Y, Ju LA. ABSTRACT P2Y12 receptor antagonists (clopidogrel, pras- Biomechanical thrombosis: the Arterial thrombosis is in part contributed by excessive ugrel, ticagrelor), inhibitors of thromboxane dark side of force and dawn platelet aggregation, which can lead to blood clotting and A2 (TxA2) generation (aspirin, triflusal) or of mechano- medicine. Stroke subsequent heart attack and stroke. Platelets are sensitive & Vascular Neurology 2019;0. protease- activated receptor 1 (PAR1) antag- to the haemodynamic environment. Rapid haemodynamcis 1 doi:10.1136/svn-2019-000302 onists (vorapaxar). Increasing the dose of and disturbed blood flow, which occur in vessels with these agents, especially aspirin and clopi- growing thrombi and atherosclerotic plaques or is caused YC and LAJ contributed equally. dogrel, has been employed to dampen the by medical device implantation and intervention, promotes Received 12 November 2019 platelet thrombotic functions. However, this platelet aggregation and thrombus formation. In such 4 Accepted 14 November 2019 situations, conventional antiplatelet drugs often have also increases the risk of excessive bleeding. suboptimal efficacy and a serious side effect of excessive It has long been recognized that arterial bleeding. Investigating the mechanisms of platelet thrombosis
    [Show full text]
  • ACTIVASE (Alteplase) for Injection, for Intravenous Use Initial U.S
    Application 103172 This document contains: Label for ACTIVASE [Supplement 5203, Action Date 02/13/2015] Also available: Label for CATHFLO ACTIVASE [Supplement 5071, Action Date 01/04/2005] HIGHLIGHTS OF PRESCRIBING INFORMATION Acute Ischemic Stroke These highlights do not include all the information needed to use • Current intracranial hemorrhage. (4.1) ACTIVASE safely and effectively. See full prescribing information for • Subarachnoid hemorrhage. (4.1) ACTIVASE. Acute Myocardial Infarction or Pulmonary Embolism • History of recent stroke. (4.2) ACTIVASE (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987 -----------------------WARNINGS AND PRECAUTIONS-----------------------­ • Increases the risk of bleeding. Avoid intramuscular injections. Monitor for ---------------------------INDICATIONS AND USAGE--------------------------­ bleeding. If serious bleeding occurs, discontinue Activase. (5.1) Activase is a tissue plasminogen activator (tPA) indicated for the treatment of • Monitor patients during and for several hours after infusion for orolingual • Acute Ischemic Stroke (AIS). (1.1) angioedema. If angioedema develops, discontinue Activase. (5.2) • Acute Myocardial Infarction (AMI) to reduce mortality and incidence of • Cholesterol embolism has been reported rarely in patients treated with heart failure. (1.2) thrombolytic agents. (5.3) Limitation of Use in AMI: the risk of stroke may be greater than the benefit • Consider the risk of reembolization from the lysis of underlying deep in patients at low risk of death
    [Show full text]
  • A First in Class Treatment for Thrombosis Prevention. a Phase I
    Journal of Cardiology and Vascular Medicine Research Open Access A First in Class Treatment for Thrombosis Prevention. A Phase I study with CS1, a New Controlled Release Formulation of Sodium Valproate 1,2* 2 3 2 1,2 Niklas Bergh , Jan-Peter Idström , Henri Hansson , Jonas Faijerson-Säljö , Björn Dahlöf 1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 2 Cereno Scientific AB, Gothenburg, Sweden 3 Galenica AB, Malmö, Sweden *Corresponding author: Niklas Bergh, The Wallenberg Laboratory for Cardiovascular Research Sahlgrenska University Hospi- tal Bruna Stråket 16, 413 45 Göteborg, Tel: +46 31 3421000; E-Mail: [email protected] Received Date: June 11, 2019 Accepted Date: July 25, 2019 Published Date: July 27, 2019 Citation: Niklas Bergh (2019) A First in Class Treatment for Thrombosis Prevention? A Phase I Study With Cs1, a New Con- trolled Release Formulation of Sodium Valproate. J Cardio Vasc Med 5: 1-12. Abstract Several lines of evidence indicate that improving fibrinolysis by valproic acid may be a fruitful strategy for throm- bosis prevention. This study investigated the safety, pharmacokinetics, and effect on biomarkers for thrombosis of CS1, a new advanced controlled release formulation of sodium valproate designed to produce optimum valproic acid concen- trations during the early morning hours, when concentrations of plasminogen activator inhibitor (PAI)-1 and the risk of thrombotic events is highest. Healthy volunteers (n=17) aged 40-65 years were randomized to receive single doses of one of three formulations of CS1 (FI, FII, and FIII). The CS1 FII formulation showed the most favorable pharmacokinetics and was chosen for multiple dosing.
    [Show full text]
  • Hypercoagulability of COVID‐19 Patients in Intensive Care Unit. A
    Article type : Brief Report Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis Mauro Panigada1, Nicola Bottino1, Paola Tagliabue1, Giacomo Grasselli1, Cristina Novembrino2, Veena Chantarangkul2, Antonio Pesenti1,3, Fora Peyvandi2,3, Armando Tripodi2 1Department of Anesthesia and Critical Care, Fondazione IRCCS Ca' Granda, Ospedale Maggiore, Milan, Italy. 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy. 3Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy. Correspondence: A. Tripodi, Via Pace 9, 20122 Milano, Italy. Phone: +39 02 55035437. FAX: +39 02 503 20723. Email: [email protected]. Word count: 1,839 Key words: Hypercoagulability, sepsis, factor VIII, von Willebrand factor, protein C, protein S This article has been accepted for publication and undergone full peer review but has not been throughAccepted Article the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/JTH.14850 This article is protected by copyright. All rights reserved ABSTRACT Background. The severe inflammatory state secondary to Covid-19 leads to a severe derangement of hemostasis that has been recently described as a state of disseminated intravascular coagulation (DIC) and consumption coagulopathy, defined as decreased platelet count, increased fibrin(ogen) degradation products such as D-dimer as well as low fibrinogen. Aims. Whole blood from 24 patients admitted at the intensive care unit because of Covid- 19 was collected and evaluated with thromboelastography by the TEG point-of-care device on a single occasion and six underwent repeated measurements on two consecutive days for a total of 30 observations.
    [Show full text]